The KRAS-G12C inhibitor: activity and resistance
Тип публикации: Journal Article
Дата публикации: 2021-09-01
SCImago Q1
WOS Q1
БС1
SJR: 1.749
CiteScore: 11.1
Impact factor: 6.4
ISSN: 09291903, 14765500
PubMed ID:
34471232
Cancer Research
Molecular Biology
Molecular Medicine
Краткое описание
Although it has long been deemed “undruggable”, with the development of drugs specifically binding the KRAS-G12C mutant protein, clinical trials that directly inhibit oncogenic RAS have recently made promising improvements. In particular, the covalent KRAS-G12C inhibitors sotorasib and adagrasib are used to treat patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS-G12C mutations. Unfortunately, the vast majority of patients do not respond to KRAS-G12C inhibitor therapy, mainly due to intrinsic or acquired resistance caused by cellular, molecular, and genetic mechanisms. Improving the understanding of drug response in the tumor microenvironment may continue to promote the design, testing, and clinical application of KRAS-G12C inhibitors.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.
Топ-30
Журналы
|
2
4
6
8
10
12
14
16
18
20
|
|
|
bioRxiv
19 публикаций, 10.11%
|
|
|
Cancers
12 публикаций, 6.38%
|
|
|
Frontiers in Oncology
6 публикаций, 3.19%
|
|
|
Nature Communications
6 публикаций, 3.19%
|
|
|
Discover Oncology
4 публикации, 2.13%
|
|
|
International Journal of Molecular Sciences
3 публикации, 1.6%
|
|
|
Cancer Gene Therapy
3 публикации, 1.6%
|
|
|
ACS Medicinal Chemistry Letters
3 публикации, 1.6%
|
|
|
Frontiers in Immunology
3 публикации, 1.6%
|
|
|
Current Issues in Molecular Biology
2 публикации, 1.06%
|
|
|
Molecules
2 публикации, 1.06%
|
|
|
Computational and Structural Biotechnology Journal
2 публикации, 1.06%
|
|
|
Bioorganic and Medicinal Chemistry
2 публикации, 1.06%
|
|
|
Oncologist
2 публикации, 1.06%
|
|
|
Science Signaling
2 публикации, 1.06%
|
|
|
Lung Cancer
2 публикации, 1.06%
|
|
|
Biomedicines
2 публикации, 1.06%
|
|
|
Experimental Hematology and Oncology
2 публикации, 1.06%
|
|
|
Clinical Cancer Research
2 публикации, 1.06%
|
|
|
Journal of Molecular Biology
2 публикации, 1.06%
|
|
|
Journal of Molecular Structure
2 публикации, 1.06%
|
|
|
Heliyon
2 публикации, 1.06%
|
|
|
Frontiers in Pharmacology
2 публикации, 1.06%
|
|
|
Molecular Cancer Therapeutics
2 публикации, 1.06%
|
|
|
Cancer and Metastasis Reviews
2 публикации, 1.06%
|
|
|
Biochemical and Biophysical Research Communications
2 публикации, 1.06%
|
|
|
Cancer Letters
2 публикации, 1.06%
|
|
|
Journal of Personalized Medicine
2 публикации, 1.06%
|
|
|
Russian Chemical Bulletin
2 публикации, 1.06%
|
|
|
2
4
6
8
10
12
14
16
18
20
|
Издатели
|
5
10
15
20
25
30
35
40
|
|
|
Springer Nature
36 публикаций, 19.15%
|
|
|
Elsevier
33 публикации, 17.55%
|
|
|
MDPI
30 публикаций, 15.96%
|
|
|
openRxiv
19 публикаций, 10.11%
|
|
|
Frontiers Media S.A.
14 публикаций, 7.45%
|
|
|
Wiley
9 публикаций, 4.79%
|
|
|
American Chemical Society (ACS)
9 публикаций, 4.79%
|
|
|
Taylor & Francis
6 публикаций, 3.19%
|
|
|
American Association for Cancer Research (AACR)
5 публикаций, 2.66%
|
|
|
Spandidos Publications
2 публикации, 1.06%
|
|
|
Society for Translational Oncology
2 публикации, 1.06%
|
|
|
American Association for the Advancement of Science (AAAS)
2 публикации, 1.06%
|
|
|
Royal Society of Chemistry (RSC)
2 публикации, 1.06%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 публикации, 1.06%
|
|
|
Bentham Science Publishers Ltd.
2 публикации, 1.06%
|
|
|
AME Publishing Company
2 публикации, 1.06%
|
|
|
De Gruyter Brill
1 публикация, 0.53%
|
|
|
Impact Journals
1 публикация, 0.53%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 публикация, 0.53%
|
|
|
Tomsk Cancer Research Institute
1 публикация, 0.53%
|
|
|
Public Library of Science (PLoS)
1 публикация, 0.53%
|
|
|
American Society of Clinical Oncology (ASCO)
1 публикация, 0.53%
|
|
|
SAGE
1 публикация, 0.53%
|
|
|
Annual Reviews
1 публикация, 0.53%
|
|
|
BMJ
1 публикация, 0.53%
|
|
|
Hans Publishers
1 публикация, 0.53%
|
|
|
Oxford University Press
1 публикация, 0.53%
|
|
|
5
10
15
20
25
30
35
40
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Войти с ORCID
Метрики
191
Всего цитирований:
191
Цитирований c 2025:
87
(46.28%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Liu J. et al. The KRAS-G12C inhibitor: activity and resistance // Cancer Gene Therapy. 2021. Vol. 29. No. 7. pp. 875-878.
ГОСТ со всеми авторами (до 50)
Скопировать
Liu J., Kang R., Tang D. The KRAS-G12C inhibitor: activity and resistance // Cancer Gene Therapy. 2021. Vol. 29. No. 7. pp. 875-878.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1038/s41417-021-00383-9
UR - https://doi.org/10.1038/s41417-021-00383-9
TI - The KRAS-G12C inhibitor: activity and resistance
T2 - Cancer Gene Therapy
AU - Liu, Jiao
AU - Kang, Rui
AU - Tang, Daolin
PY - 2021
DA - 2021/09/01
PB - Springer Nature
SP - 875-878
IS - 7
VL - 29
PMID - 34471232
SN - 0929-1903
SN - 1476-5500
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2021_Liu,
author = {Jiao Liu and Rui Kang and Daolin Tang},
title = {The KRAS-G12C inhibitor: activity and resistance},
journal = {Cancer Gene Therapy},
year = {2021},
volume = {29},
publisher = {Springer Nature},
month = {sep},
url = {https://doi.org/10.1038/s41417-021-00383-9},
number = {7},
pages = {875--878},
doi = {10.1038/s41417-021-00383-9}
}
Цитировать
MLA
Скопировать
Liu, Jiao, et al. “The KRAS-G12C inhibitor: activity and resistance.” Cancer Gene Therapy, vol. 29, no. 7, Sep. 2021, pp. 875-878. https://doi.org/10.1038/s41417-021-00383-9.
Ошибка в публикации?